This inventor holds 41 USPTO granted patents and 7 published patent applications and 9 EPO patents, primarily in Nuclear Transport Modulators. Top assignees: Karyopharm Therapeutics Inc., Decode Genetics Ehf, Biogen Ma Inc.. Active years: 2002-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Westley Hills, NY (US) (2002)
- Wesley Hills, NY (US) (2002 - 2004)
- Northboro, MA (US) (2007 - 2023)
Company Filing History:
17 out of 44 
11 out of 49 
6 out of 269 
Years Active: 2002-2025
Areas of Expertise:
Title: **Vincent Premaratna Sandanayaka: Innovator in Nuclear Transport Modulators**
Introduction
Vincent Premaratna Sandanayaka is an accomplished inventor based in Northboro, MA, with a remarkable collection of 40 patents to his name. His extensive research and innovative contributions have significantly advanced the field of nuclear transport modulation, particularly in the context of therapeutic applications.
Latest Patents
One of his most recent patents focuses on "Hydrazide containing nuclear transport modulators and uses thereof." This invention relates to nuclear transport modulators, specifically CRM1 inhibitors, and introduces a compound represented by structural formula I or a pharmaceutically acceptable salt thereof. The invention outlines the synthesis and application of this compound in the treatment, modulation, and prevention of physiological conditions linked to CRM1 activity. Additionally, he has developed another patent titled "Nuclear transport modulators and uses thereof," which covers compounds of formula I and their pharmaceutically acceptable salts, solvates, or hydrates. This patent provides details on pharmaceutical compositions encompassing these compounds and includes methodologies for treating various disorders related to CRM1 activity.
Career Highlights
Vincent has had an impressive career trajectory, contributing his expertise to notable organizations such as Karyopharm Therapeutics Inc. and Decode Genetics Ehf. His work at these companies has been instrumental in the development of cutting-edge therapies that harness the potential of nuclear transport modulation.
Collaborations
Throughout his career, Vincent has collaborated with esteemed professionals in the field, including Sharon Shechter and Sharon Shacham. These partnerships have fostered a dynamic environment for innovation, allowing for the exchange of ideas and accelerating advancements in the development of essential therapeutic agents.
Conclusion
Vincent Premaratna Sandanayaka stands out as a pioneering figure in the realm of nuclear transport modulation. His substantial portfolio of patents and collaborative efforts reflects his commitment to enhancing medical science and improving patient outcomes through innovative therapeutic solutions. His contributions are noteworthy and emphasize the vital role of inventors in advancing healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile